Assessment of insulin resistance in lean women with polycystic ovary syndrome
In primary prevention practice, HOMA-M120 and Sib (Avignon et al.) seem to adequately replace the euglycemic-hyperinsulinemic clamp in lean and overweight/obese PCOS patients, respectively.
Andrea Morciano, M.D., Federica Romani, M.D., Francesca Sagnella, Ph.D., Elisa Scarinci, M.D., Carola Palla, M.D., Francesca Moro, M.D., Anna Tropea, Ph.D., Caterina Policola, M.D., Silvia Della Casa, M.D., Maurizio Guido, M.D., Antonio Lanzone, M.D., Rosanna Apa, Ph.D.
Volume 102, Issue 1, Pages 250–256.e3
To develop and validate a specific simple measure of insulin sensitivity using oral glucose tolerance test (OGTT) values for lean polycystic ovary syndrome (PCOS) women.
Gynecologic Outpatient Clinic of University Hospital, affiliated with Unit of Gynecologic Endocrinology.
Totals of 201 lean and 198 overweight/obese (ov-ob) nondiabetic PCOS patients were retrospectively selected.
Main Outcome Measure(s):
All patients underwent OGTT, euglycemic-hyperinsulinemic clamp, and androgenic and biochemical assays. The predictive performance of each insulin resistance (IR) index was analyzed with the use of receiver operating characteristic (ROC) curves.
Higher correlation coefficients with clamp studies were obtained with the Belfiore Area (RS = 0.579) and the homeostasis-model assessment (HOMA)-M120 (RS = −0.576) in lean PCOS patients and with the Sib (RS = 0.697) in ov-ob PCOS patients. The best predictive index of IR in lean PCOS was a HOMA-M120 value of ≥12.8 or more (area under the ROC curve [AUC] 92.4%). In the ov-ob PCOS population, the best predictive performance was obtained by a Sib of ≤10.2 or less (AUC 85.7%).
IR should be assessed in all PCOS women, both lean and ov-ob subjects. The HOMA-M120 resulted as a very simple tool, validated specifically for the lean PCOS woman whose cardiometabolic impairment is more frequently misunderstood.